ARTICLE | Clinical News
GLPG0974: Phase IIa data
June 23, 2014 7:00 AM UTC
Top-line data from a double-blind, placebo-controlled, European Phase IIa trial in 45 patients with mild to moderate UC showed that the reduction in neutrophil influx achieved with twice-daily 200 mg ...